全球抗癌药物市场 – 行业趋势及 2030 年预测

抗癌药物市场分析及规模

抗癌药，也称为抗肿瘤药，是一种对治疗恶性或癌性疾病有效的药物。抗癌药有几大类，包括烷化剂、抗代谢物、天然产物和激素。此外，还有许多药物不属于这些类别，但具有抗癌活性，因此可用于治疗恶性疾病。化疗一词通常等同于使用抗癌药物，尽管它更准确地是指使用化学化合物来治疗疾病。

Data Bridge Market Research 分析，全球抗癌药物市场在 2022 年为 120,000.00 亿美元，到 2030 年将飙升至 297,000.00 亿美元，预计在预测期内的复合年增长率为 12.0%。这表明了市场价值。由于对药物的需求不断增长，“口服”在抗癌药物市场的“给药途径”部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

抗癌药物市场范围和细分

Market Definition

The treatment of cancer is complicated in that the drugs used target human cells, albeit cells that have undergone genetic changes and are dividing at a fast and uncontrolled rate. However, certain anti-cancer drugs can differentiate to some degree between normal tissue cells and cancer cells, and the rate at which cancer cells proliferate may play a role in the apparent selectivity of agents.

Global Anti-Cancer Drug Market Dynamics

Drivers

• Increasing Prevalence of Cancer to Augment Market Growth

A growing number of the cancer incidence rate has increased to make it the second leading cause of death after cardiovascular disorders. Environmental factors such as tobacco smoking, changing diet patterns, urbanization, and extended post-reproductive lifespan are responsible for this phenomenon. For instance, according to the World Health Organization (WHO), cancer is a growing burden, and the number of new cancer cases is going to rise from 18.1 million in 2018 to 29.4 million by 2040. Therefore, the increasing prevalence of cancer is expected to boost the demand for the global oncology cancer drugs market during the forecast period. Furthermore, the rising awareness regarding cancer among the population is anticipated to favor the global market in the upcoming years.

• Presence of a Strong Pipeline of Drugs to Spur Growth Opportunities

The pace of change in the treatment of cancer is accelerating. A cluster of innovative treatments, often combined with other new or existing medicines, are emerging from the research and development pipeline. Many pharma companies are investing in these research activities of novel drugs for the treatment of cancer. For instance, in June 2019, Pfizer acquired Array BioPharma with an aim to expand its oncology presence and pipeline, starting with an approved combination therapy for melanoma that is now in phase 3 trial for a form of metastatic colorectal cancer. This, coupled with the growing preference for biosimilar and biologics entering the market, is projected to augment the market growth.

• Growing investment in healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further expected to create lucrative market opportunities.

Opportunities

Furthermore, an upsurge in the public-private funding for target research activities, rising demand for chronic diseases treatments using advanced drugs, and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising internet penetration rate, increasing adoption of arthroscopic surgeries, rise in the elderly and obese population globally, and increasing per capita expenditure on health care will further expand the market's growth rate in the future.

Restraints/Challenges

On the other hand, high costs associated with research and development proficiencies, limited infrastructural facilities, high costs associated with aesthetics, and a dearth of awareness in backward economies are expected to obstruct market growth. Also, the lack of favorable reimbursement scenarios and technology penetration in developing economies, the heavy customs duty imposed on medical devices, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

This global anti-cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-cancer drug market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In June 2021 – Bayer AG announced that they entered into an agreement to acquire of Noria Therapeutics Inc. and PSMA Therapeutics Inc. Through this agreement, Bayer will have exclusive rights to the company’s investigational compound. This acquisition will help Bayer to expand their oncology portfolio.
• In April 2021– Sanofi announced that they have acquired Tidal Therapeutics, a pre-clinical biotech company responsible for the development of an mRNA based research platform. This acquisition will help Sanofi leverage this new technology platform to expand its research capabilities in the field of oncology, immunology and other disease areas.

Global Anti-Cancer Drug Market Scope

The global anti-cancer drug market is segmented on the basis of indication, drug, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Breast Cancer
• Blood Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Gynaecologic Cancer
• Lung Cancer
• Others

Drug

• Cytotoxics
• Hormonal Therapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Anti-Cancer Drug Market Regional Analysis/Insights

The global anti-cancer drug market is analysed, and market size insights and trends are provided by country, indication, drug, route of administration, end-users and distribution channel as referenced above.

The countries covered in the anti-cancer drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

北美有望主导抗癌药物市场，因为该地区拥有强大的医疗设施基础、主要市场参与者的强大影响力、慢性病病例的增加以及研究活动数量的增加。

由于人们生活方式的快速改变、该地区研究活动的不断增多、大量未开发的市场、庞大的人口数量以及该地区对优质医疗服务的需求不断增长，预计亚太地区将在 2023 年至 2030 年的预测期内出现显著增长。

报告的国家部分还提供了影响单个市场影响因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。

医疗保健基础设施增长安装基础和新技术渗透

全球抗癌药物市场还为您提供了详细的市场分析，包括每个国家/地区资本设备医疗保健支出的增长、全球抗癌药物市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对全球抗癌药物市场的影响。数据适用于 2010-2020 年的历史时期。

竞争格局及全球抗癌药物市场份额分析

全球抗癌药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对抗癌药物市场的关注有关。

全球抗癌药物市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 基因泰克公司（美国）
• 诺华公司（瑞士）
• 辉瑞公司（美国），
• 百时美施贵宝公司（美国），
• 葛兰素史克公司（英国），
• 礼来公司（美国），
• 阿斯利康（英国）、
• 赛诺菲（法国）
• 拜耳公司（德国）

SKU-52871